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298Visceral stent patency in fenestrated stent grafting
for abdominal aortic aneurysm repair
Frederike A. B. Grimme, MD,a,b Clark J. Zeebregts, MD, PhD,a Eric L. G. Verhoeven, MD, PhD,c,d
Foppe Bekkema, MANP,a Michel M. J. P. Reijnen, MD, PhD,b and Ignace F. J. Tielliu, MD, PhD,a
Groningen and Arnhem, The Netherlands; Nürnberg, Germany; and Leuven, Belgium
Objective: Fenestrated endovascular abdominal aortic aneurysm repair (F-EVAR) has been introduced for treatment of
aneurysms in which visceral arteries are incorporated. Patency of target vessels has been reported to be excellent. Results
of the use of stent grafts to accommodate visceral arteries in F-EVAR are presented in this study, including an overview of
factors that affect outcome.
Methods: All patients treated with fenestrated stent grafts in a single center between November 2001 and October 2011
were reviewed. Patients treated for suprarenal, juxtarenal, and infrarenal short-necked aortic aneurysms were included.
Patients with thoraco-abdominal aneurysms or aneurysms treated with grafts with ﬁxed side branches were excluded.
Polytetraﬂuoroethylene covered stents were used routinely since June 2005. Target vessels and stents were examined
using computed tomography angiography reconstructions. Primary end points were primary patency, deﬁned as the
absence of occlusion, and loss of renal function. Secondary end points were technical success, stenosis (deﬁned as a $50%
angiographic diameter reduction), stent fracture, and mortality.
Results: A total of 138 patients with a median age of 73 years (range, 50-91 years) met the inclusion criteria. Median
computed tomography angiography follow-up was 13 months (range, 1-97 months). In total, 392 target vessels were
provided with 140 scallops and 252 fenestrations. Visceral stents (Lgrafts) were placed in 254 target vessels. Technical
success was obtained in 249 arteries (98.0%). Overall stent patency of target vessels was 95.7% at 1 year and 88.6% at
4 years. Renal artery stent patency was 97.4% at 1 year and 91.2% at 4 years (96.8% and 89.1% for uncovered stents; 97.3%
and 92.4% for covered stents, respectively). There was no signiﬁcant difference in patency between covered and uncovered
stents in renal arteries (P [ .71). Renal artery stenosis occurred in 26 stented arteries (11.3%) and occlusion in seven
arteries. Renal artery stent stenosis occurred signiﬁcantly more in uncovered than in covered stents (P [ .04). Stent
fractures occurred more in uncovered than in covered stents (P [ .01) and was associated with a signiﬁcantly lower
visceral stent patency rate (P < .01). During follow-up, 13 patients developed permanent renal function impairment
(9.4%), of which two required permanent dialysis (1.4%). Renal dysfunction was signiﬁcantly associated with renal stent
occlusion or stenosis (P < .01).
Conclusions: Patency rates of visceral artery stent (egrafts) in F-EVAR were 95.7% at 1 year and 88.6% at 4 years. Patency
rates were affected by stent fractures, which occurred more in uncovered compared with covered stents. Renal artery stent
stenosis occurred more in uncovered compared with covered stents. Renal dysfunction was signiﬁcantly associated with
renal stent occlusion or stenosis. (J Vasc Surg 2014;59:298-306.)Endovascular abdominal aortic aneurysm repair
(EVAR) was introduced in 1986.1 Since then, the use of
the technique has evolved from treating infrarenal abdom-
inal aortic aneurysms (AAAs) to more complex fenestratedthe Department of Surgery, Division of Vascular Surgery, University
edical Center Groningen, University of Groningen, Groningena; the
epartment of Surgery, Rijnstate Hospital, Arnhemb; the Department
Vascular and Endovascular Surgery, Klinikum Nürnberg, Nürnbergc;
d the Department of Vascular Surgery, University Hospital Leuven,
uven.d
or conﬂict of interest: Dr Verhoeven has received educational grants
d is a consultant for Cook Inc, W. L. Gore & Associates, Siemens,
d Atrium-Maquet.
rint requests: Ignace F. J. Tielliu, MD, PhD, Department of Surgery,
ivision of Vascular Surgery, University Medical Center Groningen,
niversity of Groningen, PO Box 30.001, 9700 RB Groningen, The
etherlands (e-mail: i.f.j.tielliu@umcg.nl).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2014 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2013.08.005(F-EVAR) and branched stent grafting for juxta- and
suprarenal AAAs.2,3 No randomized controlled trials
comparing F-EVAR and open repair have been conducted.
Retrospective cohort studies, however, showed that the
30-day mortality has been reduced from 3.6% for open
repair to 1.4% for F-EVAR.4
Major complications of endovascular repair of juxta-
and suprarenal aneurysms include renal failure and mesen-
teric ischemia.5 Few reports described details on the
outcome of visceral artery stenting in F-EVAR. Overall esti-
mated 1-year patency of visceral target vessels was reported
up to 92%, with a renal artery patency rate of 85%.4 Our
group reported a cumulative visceral target vessel patency
(275 target vessels in 100 patients) of 93.3% at 5 years.6
Few studies focused on renal-related outcome of
F-EVAR. In one report, baseline renal dysfunction was
a strong predictor for mortality. Adverse renal events,
including renal artery stenosis, renal artery occlusion, and
hemodialysis, occurred in 40% of the patients within the
ﬁrst year after treatment. Renal artery stenosis (>50%) after
treatment was detected in 10 of 142 (7.0%) and occlusion
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signiﬁcantly more stenoses in uncovered stents (10%)
compared with covered stents (2.5%).8 Recently, Mastracci
et al showed low branch-related death after F-EVAR for
thoraco-abdominal and juxtrarenal aneurysms (three of
650 patients), with freedom of reintervention of 89% at
5 years.9
Little is known about factors that may affect outcome
of visceral artery stenting in F-EVAR. Possible factors are
preprocedural renal function,7 aneurysm size, visceral
artery ostium stenosis, the angle of the target vessel with
the aorta, and failure of material.
This study reports on the outcome of visceral artery
stenting after F-EVAR of abdominal aneurysms in terms
of stent patency and technical failure. Results of covered
stents in target vessels are analyzed speciﬁcally. Addition-
ally, factors inﬂuencing patency are analyzed.
METHODS
Patients. All patients treated with fenestrated and
branched stent grafts in our tertiary referral center were
enrolled in an investigational device protocol database.
Indications for treatment with F-EVAR were abdominal
short-necked, juxtarenal, or suprarenal AAAs with a diam-
eter $55 mm in men and $50 mm in women, as well as
AAAs <55 mm in conjunction with an iliac artery aneu-
rysm diameter $35 mm. All patients treated for such an
aneurysm in a 10-year period (November 2001 to October
2011) were analyzed. In this study, thoraco-abdominal
aneurysms were excluded. Demographic details on
comorbidity were noted.
Preoperative assessment. Thin-cut (#1 mm) spiral
computed tomography angiography (CTA) was performed
to assess aneurysm morphology and determine position and
patency of visceral vessels. For all patients, a customized
fenestrated device based on the three-part Cook Zenith
System (William A. Cook Australia, Ltd, Brisbane,
Australia) was constructed.10 The clock position of the
fenestrations was noted in degrees where 0 equals the 12
o’clock position, 90 the 9, 90 the 3, and 180 the 6
o’clock position. Renal artery angulation in relation to the
aorta was measured on coronal multiplanar reconstructions
after adjustment of the central lumen line of the aorta in the
sagittal plane. Grafts were ﬁtted with diameter-reducing ties
to allow partial deployment before catheterization of side
branches and ﬁnal orientation of the stent graft. In this way,
both rotational and craniocaudal repositioning of the device
was made possible to allow catheterization of target vessels.
Fenestrations included scallops and small and large fenes-
trations. In target vessels, three types of stents were used:
uncovered stents (Genesis stent; Cordis Corporation,
Miami Lakes, Fla) and polytetraﬂuoroethylene-covered
stents (Jostent stent graft; Abbott Laboratories, Abbott
Park, Ill), and Advanta V12 stent graft (Atrium Medical,
Hudson, NH). Fenestrations had radiopaque markers to
enable accurate alignment during implantation.
Procedure. The detailed operative technique has been
described before.10-13 Brieﬂy, patients received heparin(5000 IU) intravenously at the time when the ﬁrst sheath
was introduced, and an additional dose of 2500 IU was
administered after 90 minutes. Since 2010, we have been
monitoring the activated clotting time to adjust heparin
dosage to an activated clotting time of 250 seconds. The
stent grafts in the fenestrations were ﬂared with a 12 mm 
20 mm percutaneous transluminal angioplasty balloon to
improve apposition and ﬁxation at the level of the fenes-
tration and in most cases also with a compliant balloon
(Reliant Stent Graft Balloon Catheter; Medtronic, Min-
neapolis, Minn) for additional ﬂaring. After stenting of
each target vessel, a selective angiography through the
ﬂaring balloon catheter was performed to demonstrate
patency and outﬂow. After the procedure, completion
angiography was carried out to conﬁrm overall vessel
patency and exclusion of the aneurysm. Procedural data
including contrast volume and technical features of stent
placement were collected.
Follow-up. Patients were followed up with abdominal
X rays during admission, CTA at 6 weeks, and abdominal
X rays, duplex, CTA, and renal function analysis yearly
thereafter to assess (target) vessel patency, stent fracture,
endoleak, and migration. X rays were performed in four
views, including anteroposterior, lateral, and left and right
anterior oblique.
All patients received anti-platelet therapy after the
procedure. Acetylsalicylic acid was given on the day of
the procedure. Clopidogrel was started after removal of
spinal or epidural catheters and for a minimum duration
of 2 months. In addition, renal function and blood pressure
were monitored.
Three-dimensional volumetric CTA reconstructions
were made and analyzed on an Aquarius workﬂow platform
(TeraRecon, Foster City, Calif). In all reconstructions,
diameters were measured at the level of the fenestration,
in-stent, and at the distal end of the stent. In addition,
any changes in the conﬁguration of the stents were noted.
Target vessel angulations in relation to the aorta were
noted in degrees, before and after the procedure. The
aneurysm sac diameter was measured perpendicular to
the axis of the aorta, in two directions, before and after
the procedure.
Deﬁnitions and statistics. Reporting standards for
endovascular aortic aneurysm repair and renal artery stenting
were used for deﬁnitions and analysis of outcome.14-17
Short-necked aneurysms were deﬁned as having a proximal
neck length below the lowest renal artery of 4 to 12 mm.
Juxtarenal aneurysms were deﬁned as AAAs with aneurysmal
extension up to the inter-renal aorta, or AAAs with normal
inter-renal aorta but aneurysmal involvement of one of the
renal artery origins. Suprarenal aneurysms were deﬁned as
extending above the renal aorta but below the celiac trunk.
Target vessels were deﬁned as vessels for which a scallop
or fenestration was needed. Stenting of a target vessel was
considered technically successful when there was a <30%
residual stenosis, and the stent was positioned within the
target vessel. Technical success of F-EVAR was deﬁned as
a completed endovascular procedure with patent target
Table I. Complications
Procedural complications
Dislocation prosthetic limb
(n ¼ 1)
Fem-fem bypass
Disconnection stents
prosthetic
limb (n ¼ 1)
Plug CIA þ fem-fem bypass
Dislocation prosthetic limb
(n ¼ 1)
Covered stent placement
Unsuccessful target vessel
stenting (n ¼ 4)
Overstented
Endoleak type 1 (n ¼ 5) Followed up
Dissection (n ¼ 2) Followed up
Rupture femoral artery
(n ¼ 1)
Surgical interposition graft
Migration aortic endograft
(n ¼ 1)
Endovascular repositioning graft
caudally
Occlusion renal artery
(n ¼ 1)
Retrogradely revascularization
Postoperative complications
Pulmonary (n ¼ 6) Temporary injury
Cardiac event (n ¼ 12) One patient sustained damage
Ischemic cerebrovascular
accident (n ¼ 2)
Both patients remaining
neurologic deﬁcit
Delirium (n ¼ 3) Temporary impairment
Gastrointestinal (n ¼ 8) Two patients deceased because of
bowel ischemia
Urinary tract infection/
retention (n ¼ 10)
Temporary impairment
Decrease renal function
(n ¼ 13)
Five patients permanent renal
function loss
Wound infection/
hematoma (n ¼ 6)
Temporary injury
Non-infectious fever
(n ¼ 3)
Temporary injury
Other (n ¼ 6) Temporary injury
CIA, Common iliac artery.
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I or III.
In follow-up of target vessels and stents, an angio-
graphic diameter reduction of >50%, comparing diameters
distal from the stenosis and at the stenosis was considered
hemodynamically signiﬁcant and was therefore appointed
as “stenosis.”15,18,19 Additionally, occlusions were noted.
Physiologic renal function was monitored using calculated
estimated glomerular ﬁltration rate (eGFR), determined by
using the abbreviated Modiﬁcation of Diet in Renal
Disease study equation: eGFR (mL/min/1.73 m2) ¼
186  (serum creatinine (mmol/L))1.154  (age)0.203
( 0.742; if female).20 Renal dysfunction was deﬁned as
an eGFR lower than 60 mL/min/1.73 m2. Renal function
impairment or decrease was deﬁned as a 30% reduction of
eGFR. Transient renal function impairment was deﬁned as
a temporary reduction of at least 30% eGFR that was
restored during follow-up. Permanent renal function
impairment was deﬁned as a permanent >30% reduction
of eGFR without improvement.
Primary patency was deﬁned as the uninterrupted
patency in absence of occlusion, with no procedures per-
formed on the vessel or stent to prevent occlusion.15
Statistical analysis was done with SPSS version 19.0
(Statistical Package for the Social Sciences, Inc., Chicago,
Ill). Variables were expressed as mean 6 one standard
deviation in case of normal distribution, or as median
plus range in other distributions.
Patency was estimated using Kaplan-Meier survival
analysis. To test for statistically signiﬁcant survival differ-
ences, the generalized Wilcoxon (Breslow) or the log-
rank (Mantel-Cox) tests were used. Patency rates were
based on a per-artery analysis. Additionally, a per-patient
analysis was performed to assess for predictive factors that
may affect patency.
Differences between groups were determined using
analysis of variance with P < .05 considered signiﬁcant.
Primary end points were primary patency and renal
function. Secondary end points were technical success,
stenosis, stent fracture, and mortality.
RESULTS
Outcome of F-EVAR. F-EVAR was performed in
138 patients, including 107 primary procedures (77.5%)
and 31 F-EVAR procedures (22.5%) after previous open
surgical AAA repair (n ¼ 19), EVAR (n ¼ 8), or other
aortic repairs (n ¼ 4). One conversion to an open proce-
dure was due to migration of the endograft and occlusion
of both renal arteries during the procedure.
Technical success of F-EVAR was obtained in 127 of
138 procedures (92.0%). Within 30 days after the proce-
dure, 69 complications were noted in 31 patients (22.3%;
Table I). At completion angiography, there were ﬁve
type I endoleaks, which were all followed up on. At the
ﬁrst follow-up, two of the ﬁve type I endoleaks had per-
sisted but resolved with conservative treatment. Type II
endoleaks discovered at completion angiography per-
sisted in 13 of the 18 cases at ﬁrst follow-up. In onepatient, a type II endoleak caused by three large lumbar
arteries was treated surgically. Follow-up revealed another
type I and eight type II endoleaks, of which one type II
endoleak was treated by coil embolization. The reason
for treating type II endoleaks was ongoing aneurysm
growth.
One F-EVAR procedure was converted to an open
procedure and therefore not included for analysis. Median
age of the patients was 73 years (range, 50-91 years).
Demographic details are described in Table II. CTA
follow-up was not available for 11 patients (8.0%), and
therefore they were considered lost to follow-up. Median
CTA follow-up for the other 127 patients was 13 months
(range, 1-97 months). CTA follow-up at 1, 2, and 4 years
was available for 72, 50, and 15 patients, respectively.
Renal function impairment occurred in four patients, and
therefore no CTA was performed. Additionally, CTAs
performed in other hospitals were of low quality (5-mm
slices) and therefore not adequate for three-dimensional
reconstruction and stent measurement.
Thirty-day mortality was 1.4%. Two patients died
within the ﬁrst month after the procedure, both due to
bowel ischemia. During follow-up, 56 (40.5%) patients
died, of whom 47 died (34.1%) within 5 years of the
Fig 1. Kaplan-Meier curve showing overall patient survival. SE,
Standard error.
Table III. Characteristics of target vessels
Total Scallop, No. Fenestration, No.
Renal artery 261 33 228
No stent 31 26 5
Uncovered stent 71 6 65
Covered stent 153 1 152
Combination 1 - 1
Unknown stent type 5 - 5
SMA 110 87 23
No stent 87 86 1
Uncovered stent 6 1 5
Covered stent 9 - 9
Combination 7 - 7
Unknown stent type 1 - 1
Celiac trunk 21 20 1
No stent 20 20 -
Uncovered stent 0 - -
Covered stent 1 - 1
SMA, Superior mesenteric artery.
Table II. Patient characteristics
Total (N ¼ 138)
No. %
Male 123 89.1
Smoking 79 58.5
Hypertension 120 87.6
Diabetes mellitus 21 15.2
Coronary artery disease 89 69.5
Neurologic disease 25 18.1
Pulmonary disease 64 48.9
Renal disease 49 35.5
Age, years (range) 73 (50-91)
Table IV. Fenestrated endovascular aneurysm repair
(F-EVAR) conﬁguration
Type No. %
Scallop SMA, fenestrated renal arteries 77 55.8
Scallop celiac trunk, fenestrated SMA, fenestrated
renal arteries
20 14.5
Scallop renal arteries 8 5.8
One scallop renal artery, one fenestrated renal artery 7 5.1
Scallop SMA, one fenestrated/scallop renal artery 6 4.3
One fenestrated renal artery 6 4.3
Other 14 10.2
SMA, Superior mesenteric artery.
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(4.3%). In one patient, dislocation of the main body had
resulted in a large endoleak. The other patients died as
a result of other aneurysm-related problems (infection of
the prosthesis, bowel ischemia, and mycotic aneurysm).
The cumulative survival probability of patients 1 and 4 years
after the procedure was 89.2% and 62.5%, respectively
(Fig 1).
Target vessels. In total, 392 target vessels in 138
patients were provided with 140 scallops and 252 fenestra-
tions. Stents were placed in 254 target vessels. Details of
target vessels and stent types that were used are described
in Table III and F-EVAR conﬁgurations in Table IV.
Technically successful stent placement was obtained in 249
arteries (98.0%). Overall stent patency (absence of occlu-
sion or intervention) was 95.7% at 1 year and 88.6% at
4 years (Fig 2). Renal artery stenosis occurred in 26 stentedarteries (11.3%) in 24 patients and occlusion in seven
arteries (3.0%) in ﬁve patients. Freedom from occlusion in
renal artery stents was 97.4% at 1 year and 91.2% at 4 years
(96.8% and 89.1% for uncovered; 97.3% and 92.4% for
covered stents, respectively). There was no signiﬁcant
difference in renal stent patency between uncovered and
covered stents (P ¼ .70).
Freedom from stenosis in renal artery stents (occluded
stents were excluded in this analysis) was 90.0% at 1 year
and 71.4% at 4 years (84.5% and 58.9% for uncovered
stents; 92.9% and 86.7% for covered stents, respectively).
Stenosis was more prevalent in uncovered than in covered
stents (P ¼ .04; Fig 3). At 4 years, the combined outcome
of freedom from stenosis or occlusion was 80.9% for
covered stents and 70.7% for uncovered stents, without
signiﬁcant difference (P > .05; Fig 4).
Stent fractures (Fig 5) were seen in eight uncovered
(10.3%) and two covered stents (1.2%; P ¼ .01).
Stent fractures signiﬁcantly reduced stent patency rate
(P < .01). In total, 41 stenoses or occlusions occurred in
254 stents. In 22 cases with stenosis or occlusion, an in-
stent kink was present (53.7%), and in ﬁve cases, the stent
was fractured (12.2%). In the other 14 stents, there were
no evident changes in stent conﬁguration.
Fig 2. Kaplan-Meier survival curve showing the overall patency rate of all target vessels and the patency rate of stents
used in target vessels. SE, Standard error.
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ventions in 1.0% of the cases (four target vessels). In one
patient, the body of the endoprosthesis migrated, thereby
occluding both renal arteries. The body was repositioned
surgically. An attempt to recanalize two renal arteries in
two patients failed.
Univariate analysis (log-rank) showed no signiﬁcant
inﬂuence of diabetes (P ¼ .95), smoking (P ¼ .07), hyper-
tension (P ¼ .97), pulmonary status (P ¼ .22), cardiac
status (P ¼ .20), carotid disease (P ¼ .12), renal status
(P ¼ .24), or aneurysm sac size (P ¼ .53) on stent patency.
Renal outcome. Preprocedural renal dysfunction was
noted in 49 patients (35.5%). There were no patients on
hemodialysis before the procedure. The median volume
of contrast used (270 mg/mL iodine solution) was
195 mL (range, 80-350 mL). Renal function impairment
was not associated with contrast load (P ¼ .63).
Permanent renal function impairment occurred in 13
patients (9.4%), within the ﬁrst week after the procedure
in four of them. Temporary renal function impairment
was seen in 57 patients (41.3%), within the ﬁrst week after
the procedure in 18 of them (16.8%). Two patients devel-
oped dialysis-dependent renal function loss, caused by
bilateral occlusion of the stented renal arteries. One of
these patients received kidney transplantation. Transient
and permanent renal function impairment did not signiﬁ-
cantly occur more in patients with preoperative renal
dysfunction (P ¼ .58 and P ¼ .77, respectively) and wasnot signiﬁcantly associated with mortality (P ¼ .21). A
pre-procedural eGFR <60 was signiﬁcantly associated
with mortality (P ¼ .04). Renal artery stenosis or occlusion
lead to a >30% decrease in eGFR in eight patients. Renal
function impairment in general was signiﬁcantly associated
with renal stent occlusion or stenosis (P < .01).
Renal artery stenosis was seen in eight right renal
arteries and 10 left renal arteries in patients before the
procedure. Restenosis after stenting was detected in three
renal arteries (three patients) and occlusion in three renal
arteries (two patients).
Stent patency was not signiﬁcantly associated with the
angulation of the vessel before the procedure (P ¼ .71),
nor with an increase or decrease of the angulation after
the procedure (P ¼ .86). The clock position of the renal
arteries did not inﬂuence stent patency (P ¼ .60).
Mesenteric outcome. In total, 131 mesenteric vessels
(celiac trunk and superior mesenteric artery [SMA]) were
targeted. There were 107 scallops (of which one was
stented) and 24 fenestrations (of which 23 were stented;
Table III). Stents were placed in 24 mesenteric vessels in
23 patients. Due to this small group, the standard error for
calculation of survival was >10%, and therefore no reliable
stent patency rates could be calculated. During follow-up
in four patients, stenosis was noted in two SMA stents,
and occlusion occurred in one stented celiac trunk and in
two SMAs. One of these patients died after both stents in
celiac trunc and SMA had occluded (as well as both renal
Fig 3. Kaplan-Meier survival curve showing freedom from stenosis in uncovered (bare metal stent [BMS]) and covered
(polytetraﬂuoroethylene [PTFE]) stents in renal arteries (P ¼ .04). SE, Standard error.
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tion, multiorgan failure, and death of the patient.
The other three patients remained symptom-free, and
therefore no intervention was performed.
Bowel ischemia occurred in two patients in the follow-
up period after the procedure (8.7%). Apart from the one
mentioned above, one patient developed bowel ischemia
of unknown origin with a patent targeted SMA.
DISCUSSION
Results of F-EVAR in literature are generally good.
Mortality rates have been reported to be 1.4% with target
vessel patency of 93% at 5 years.4,6 The effect of F-EVAR
on target vessels, however, has not been addressed in
many articles.
In 2005, Haddad et al outlined the effect of F-EVAR
on target vessels, with special attention to the “renal side
of the story.”7 The risk for adverse renal events was 16%
in patients without preoperative renal dysfunction but
was 39% for patients with preoperative renal dysfunction.
In our study, postprocedural renal function impairment
(transient as well as permanent) was not inﬂuenced by
preoperative renal dysfunction. Haddad et al also described
that adverse renal events were associated with death, a result
we conﬁrmed in our study. The advice of Haddad et al wasto meticulously follow-up on patients and to reintervene
without hesitation when renal artery stenosis or material
failure is suspected.
Stent patency of target vessels was 95.7% at 1 year and
88.6% at 4 years in this study. These ﬁgures are similar to
target vessel patency rates according to the GLOBAL
collaborators on Advanced Stent-graft Techniques for
Aneurysm Repair (GLOBALSTAR) Registry (318 patients
and 889 target vessels, of which 670 were stented), in
which target vessel patency was 97% and 95% at 12 and
42 months, respectively.5 The GLOBALSTAR Registry,
however, did not describe stent patency separately. There-
fore patency rates are difﬁcult to compare. Additionally, the
GLOBALSTAR ﬁgures may be inﬂuenced by different
follow-up protocol. In our study, all patients received
CTA follow-up, and all stents were measured separately,
whereas the GLOBALSTAR registry did not differentiate
between “target vessel patency” and “stent patency” and
did not describe which cohort of patients were followed
up with CTA. Therefore, the inﬂuence of the use of
different deﬁnitions is unclear.
Visceral stent patency in our study was 95.7% at 1 year
and 88.6% at 4 years. Bowel ischemia after mesenterial
stent placement occurred in only two patients (8.6%).
However, both patients died as a result of multiorgan
Fig 4. Kaplan-Meier survival curve showing freedom from combined outcome of occlusion and stenosis in uncovered
(bare metal stent [BMS]) and covered (polytetraﬂuoroethylene [PTFE]) stents in renal arteries. SE, Standard error.
Fig 5. Fractured uncovered stent in superior mesenteric artery
(SMA) of 72-year-old man. Since the patient had no abdominal
complaints, no intervention was performed.
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ence outcome of stents, neither did cardiopulmonary
comorbidity. Stent patency was, however, affected by
material failure (fracture). This underlines the importance
of the materials used.Mastracci et al described freedom from secondary
intervention of 89% at 3 years after fenestrated or branched
repair, and the authors underlined the importance of metic-
ulous follow-up by imaging.21
Estimated patient survival rates are 89.2% at 1 year and
62.5% at 4 years. In the EVAR trials 1 and 2, 4-year all-
cause mortality rates were 26% and 64%, respectively.22,23
Although 30-day mortality rate in this study cohort is
1.3%, all-cause mortality rates at medium term emphasize
the need for well-thought consideration for F-EVAR in
medically compromised patients.
Natural renal artery motion during cardiac cycles can
reach up to 3 mm both near and distant from the aorta.
EVAR inhibits proximal renal artery motion, decreasing
31% in maximal movement, but does not inﬂuence distal
renal artery motion.24 However, renal stents used in
F-EVAR reduce proximal motion to 25% of preoperative
value and reduce distal renal artery motion by 20%.25 Addi-
tional to these kinetic forces created by longitudinal move-
ment of the endograft and side branches, forces (though
modest) are created solely due to mismatch between stent
graft and native anatomy.26 These forces subject stents to
repetitive stress and make them vulnerable to fracture. In
our study, covered stents showed signiﬁcantly less fractures
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ﬂuoroethylene layers in the covered stents create high
radial strength by connecting the stent struts, thereby
providing strong ﬁxation of the stent graft to the visceral
arteries. Flexibility is not compromised, and therefore
covered stents might be less prone to fatigue fracture.27
Transient renal function impairment was seen in 41.3%
and persistent renal function impairment in 9.4%. In
contrast to Haddad et al,7 renal function impairment was
not signiﬁcantly associated with preprocedural renal
dysfunction. In patients with renal artery stenosis or occlu-
sion, renal function impairment did signiﬁcantly occur
more often (P < .01).
In total, 41 stenoses or occlusions occurred in 254
stents. In 22 of these cases, there appeared to be a kink
in the stent (53.7%), and in ﬁve cases, the stent was frac-
tured (12.2%). Since stenosis and occlusion are signiﬁcantly
associated with loss of renal function, it could be advised to
perform a percutaneous transluminal angioplasty or new
stent placement when a change in stent conﬁguration
occurs.
This study is limited by the fact that in the ﬁrst years of
F-EVAR, only uncovered stents were used, whereas the
more expensive covered stents were used since 2005. There-
fore, a learning curve could have inﬂuenced stent outcome.
Loss of target vessel or stent patency was, however, equally
distributed over time from the procedure, suggesting that
loss of patency was not inﬂuenced by a learning curve. Since
2009, stents at risk for kinking (vessels under a sharp angle)
were realigned with self-expanding nitinol stents to support
a smoother passage from stent to vessel. In this F-EVAR
series, only eight target vessels were treated this way. The
effects of this realignment are therefore unknown. The
method we used to determine the angulation of target
vessels is not a validated test. However, with the use of
three-dimensional reconstructions and measurements in
the axis of the aorta and visceral arteries, we were able to
present reliable measurements. Another limitation is the
use of eGFR to address renal function. We do acknowledge
that a 24-hour urine collection would have been more
precise to address renal function. This has not been per-
formed for logistic reasons.
In literature regarding F-EVAR, different deﬁnitions of
“loss of patency,” “stenosis,” and “target vessel” are used,
as well as different techniques to assess vessel or stent
patency. Therefore it is difﬁcult to compare results.
In our study, we did not measure migration. In theory,
migration and therefore crushing of the stent between the
fenestration and artery could be related to lower visceral
stent patency. We did, however, perform a univariate anal-
ysis, which outlined that visceral stent failure did not inﬂu-
ence other stent failure within the same patient. Therefore,
we considered no inﬂuence of migration of endoprosthesis.
Finally, only 52% of the patients had a 1-year CT
follow-up and only 11% had a 4-year CT follow-up, which
inﬂuenced the results of this study.
Occlusions and stenoses of target vessels seem not to
be inﬂuenced by comorbidity, target vessel angulation,clock position, or aneurysm sac size. However, we cannot
rule out the effect of dislocation of the endoprosthesis or
the inﬂuence of preprocedural miscalculation of the sizing
and positioning of fenestrations.
CONCLUSIONS
Patency rates of visceral artery stents (egrafts) in fenes-
trated EVAR are 95.7% at 1 year and 88.6% at 4 years.
Patency rates were affected by stent fractures, which
occurred more in uncovered stents compared with covered
stents. Renal artery stent stenosis occurred more in uncov-
ered compared with covered stents. Renal dysfunction was
signiﬁcantly associated with renal stent occlusion or
stenosis.
AUTHOR CONTRIBUTIONS
Conception and design: FG, CZ, MR, IT
Analysis and interpretation: FG, CZ, IT
Data collection: FG, EV, FB, IT
Writing the article: FG, IT
Critical revision of the article: FG, CZ, EV, FB, MR, IT
Final approval of the article: FG, CZ, EV, FB, MR, IT
Statistical analysis: FG
Obtained funding: Not applicable
Overall responsibility: IT
REFERENCES
1. Volodos’ NL, Shekhanin VE, Karpovich IP, Troian VI, Gur’ev I.
[A self-ﬁxing synthetic blood vessel endoprosthesis]. Vestn Khir Im I I
Grek 1986;137:123-5.
2. Park JH, Chung JW, Choo IW, Kim SJ, Lee JY, Han MC. Fenestrated
stent-grafts for preserving visceral arterial branches in the treatment of
abdominal aortic aneurysms: preliminary experience. J Vasc Interv
Radiol 1996;7:819-23.
3. Browne TF, Hartley D, Purchas S, Rosenberg M, Van SG, Lawrence-
Brown M. A fenestrated covered suprarenal aortic stent. Eur J Vasc
Endovasc Surg 1999;18:445-9.
4. Nordon IM, Hinchliffe RJ, Holt PJ, Loftus IM, Thompson MM.
Modern treatment of juxtarenal abdominal aortic aneurysms with
fenestrated endografting and open repairea systematic review. Eur J
Vasc Endovasc Surg 2009;38:35-41.
5. Early results of fenestrated endovascular repair of juxtarenal aortic
aneurysms in the United Kingdom. Circulation 2012;125:2707-15.
6. Verhoeven EL, Vourliotakis G, Bos WT, Tielliu IF, Zeebregts CJ,
Prins TR, et al. Fenestrated stent grafting for short-necked and jux-
tarenal abdominal aortic aneurysm: an 8-year single-centre experience.
Eur J Vasc Endovasc Surg 2010;39:529-36.
7. Haddad F, Greenberg RK, Walker E, Nally J, O’Neill S, Kolin G, et al.
Fenestrated endovascular grafting: the renal side of the story. J Vasc
Surg 2005;41:181-90.
8. Mohabbat W, Greenberg RK, Mastracci TM, Cury M, Morales JP,
Hernandez AV. Revised duplex criteria and outcomes for renal stents
and stent grafts following endovascular repair of juxtarenal and thor-
acoabdominal aneurysms. J Vasc Surg 2009;49:827-37.
9. Mastracci TM. Fenestrated endografts for complex abdominal aortic
aneurysms. Perspect Vasc Surg Endovasc Ther 2010;22:214-8.
10. Verhoeven EL, Prins TR, Tielliu IF, Van Den Dungen JJ,
Zeebregts CJ, Hulsebos RG, et al. Treatment of short-necked
infrarenal aortic aneurysms with fenestrated stent-grafts: short-term
results. Eur J Vasc Endovasc Surg 2004;27:477-83.
11. Muhs BE, Verhoeven EL, Zeebregts CJ, Tielliu IF, Prins TR,
Verhagen HJ, et al. Mid-term results of endovascular aneurysm repair
with branched and fenestrated endografts. J Vasc Surg 2006;44:9-15.
JOURNAL OF VASCULAR SURGERY
306 Grimme et al February 201412. Verhoeven EL, Zeebregts CJ, Kapma MR, Tielliu IF, Prins TR, Van
Den Dungen JJ. Fenestrated and branched endovascular techniques for
thoraco-abdominal aneurysm repair. J Cardiovasc Surg (Torino)
2005;46:131-40.
13. Moore R, Hinojosa CA, O’Neill S, Mastracci TM, Cina CS.
Fenestrated endovascular grafts for juxtarenal aortic aneurysms:
a step by step technical approach. Catheter Cardiovasc Interv
2007;69:554-71.
14. Chaikof EL, Blankensteijn JD, Harris PL, White GH, Zarins CK,
Bernhard VM, et al. Reporting standards for endovascular aortic
aneurysm repair. J Vasc Surg 2002;35:1048-60.
15. Rundback JH, Sacks D, Kent KC, Cooper C, Jones D, Murphy T, et al.
Guidelines for the reporting of renal artery revascularization in clinical
trials. American Heart Association. Circulation 2002;106:1572-85.
16. Boyle JR, Thompson MM, Vallabhaneni SR, Bell RE, Brennan JA,
Browne TF, et al. Pragmatic minimum reporting standards for endo-
vascular abdominal aortic aneurysm repair. J Endovasc Ther 2011;18:
263-71.
17. Oderich GS. Reporting on fenestrated endografts: surrogates for
outcomes and implications of aneurysm classiﬁcation, type of repair,
and the evolving technique. J Endovasc Ther 2011;8:154-6.
18. Fleischmann D. Multiple detector-row CT angiography of the renal
and mesenteric vessels. Eur J Radiol 2003;45:S79-87.
19. Langenberger H, Schillinger M, Plank C, Sabeti S, Dick P, Cejna M,
et al. Agreement of duplex ultrasonography vs. computed tomography
angiography for evaluation of native and in-stent SFA re-stenosis:
ﬁndings from a randomized controlled trial. Eur J Radiol 2012;81:
2265-9.20. K/DOQI clinical practice guidelines for chronic kidney disease: eval-
uation, classiﬁcation, and stratiﬁcation. Am J Kidney Dis 2002;39:
S1-266.
21. Mastracci TM, Greenberg RK, Eagleton MJ, Hernandez AV. Dura-
bility of branches in branched and fenestrated endografts. J Vasc Surg
2013;57:926-33.
22. Endovascular aneurysm repair versus open repair in patients with
abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial.
Lancet 2005;365:2179-86.
23. Endovascular aneurysm repair and outcome in patients unﬁt for open
repair of abdominal aortic aneurysm (EVAR trial 2): randomised
controlled trial. Lancet 2005;365:2187-92.
24. Muhs BE, Teutelink A, Prokop M, Vincken KL, Moll FL,
Verhagen HJ. Endovascular aneurysm repair alters renal artery move-
ment: a preliminary evaluation using dynamic CTA. J Endovasc Ther
2006;13:476-80.
25. Muhs BE, Vincken KL, Teutelink A, Verhoeven EL, Prokop M,
Moll FL, et al. Dynamic cine-computed tomography angiography
imaging of standard and fenestrated endografts: differing effects on
renal artery motion. Vasc Endovascular Surg 2008;42:25-31.
26. Oshin OA, How TV, Brennan JA, Fisher RK, McWilliams RG,
Vallabhaneni SR. Magnitude of the forces acting on target vessel stents
as a result of a mismatch between native aortic anatomy and fenestrated
stent-grafts. J Endovasc Ther 2011;18:569-75.
27. Stoeckel D, Bonsignore C, Duda S. A survey of stent designs. Minim
Invasive Ther Allied Technol 2002;11:137-47.
Submitted May 15, 2013; accepted Aug 8, 2013.
